PulseSight to highlight new data on the role of iron and transferrin in AMD at EURETINA 2025

PulseSight Therapeutics announced the presentation of new data on iron dysregulation and the role of ferroptosis in age-related macular degeneration (AMD). This presentation will be given by Thierry Bordet, PhD, chief scientific officer of PulseSight, during the 2025 European Society of Retina Specialists Annual Congress held September 4-7 in Paris.

In collaboration with Inserm and Cochin Hospital (Paris) and using one of the largest aqueous humor datasets to date, PulseSight explored iron-transferrin imbalance in dry AMD and geographic atrophy (GA) patients compared to age-matched controlled patients.¹

The collaborative study found and confirmed elevated iron and increased transferrin saturation in aqueous humors of AMD patients.

“Ferroptosis is now a well-recognized target in AMD pathology,” Bordet said in a press release. “At PulseSight, we’ve designed a translational strategy to restore iron homeostasis and prevent ferroptosis.”

PulseSight’s lead therapy, PST-611, is a first-in-class non-viral vectorized therapy encoding transferrin to restore iron balance and preserve retinal structure and function in dry AMD and GA.¹ PST-611 encodes the human transferrin protein, which is a crucial regulator of iron homeostasis, and only requires re-treatment every four to six months.

The recent findings further support the development of PST-611, which entered a phase 1 clinical trial (PST-611-CT1) in January 2025.² The company announced the successful dosing of the first patient in the phase 1 clinical trial PST-611-CT1 in July 2025.³

PST-611-CT1 is a single ascending dose study aimed at establishing the safety profile of PST-611 and validating the maximal tolerated dose in 6-12 patients enrolled with dry AMD and GA.³

“With PST-611, we combine mechanistic relevance, long-lasting efficacy, and a de-risked delivery platform,” Bordet said.

Additionally, Bordet will present topline data from a specific study conducted to provide mechanistic insights into the role of transferrin in preventing ferroptosis. The study’s full results have been submitted for peer-reviewed publication.¹

Reference:

1. Morningstar I. PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025. Morningstar, Inc. Published September 4, 2025. Accessed September 4, 2025. https://www.morningstar.com/news/globe-newswire/1001126185/pulsesight-therapeutics-provides-new-insights-into-the-role-of-iron-and-transferrin-in-amd-supporting-its-pst-611-vectorized-therapy-for-dry-amdgeographic-atrophy-at-euretina-2025

2. PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy – Pulsesight. Pulsesight.com. Published 2025. Accessed September 4, 2025. https://pulsesight.com/2025/01/14/pulsesight-therapeutics-announces-the-initiation-of-the-clinical-plan-of-pst-611-transferrin-vectorized-therapy-for-dry-amd-geographic-atrophy/

3. Filkins K. PulseSight doses first patient in PST-611-CT1. Ophthalmology Times. Published July 9, 2025. Accessed September 4, 2025. https://www.ophthalmologytimes.com/view/pulsesight-doses-first-patient-in-pst-611-ct1